OBJECTIVE: To examine the association between baseline renal insufficiency and mortality among adults initiating antiretroviral therapy (ART) in an urban African setting. DESIGN: Open cohort evaluation. METHODS: We examined mortality according to baseline renal function among adults initiating ART in Lusaka, Zambia. Renal function was assessed by the Cockcroft-Gault method, the Modification of Diet in Renal Disease equation, and serum creatinine. RESULTS: From April 2004 to September 2007, 25 779 individuals started ART with an available creatinine measurement at baseline. When creatinine clearance was calculated by the Cockcroft-Gault method, 8456 (33.5%) had renal insufficiency: 73.5% were mild (60-89 ml/min), 23.4% moderate (30-59 ml/min), and 3.1% severe (<30 ml/min). Risk for mortality at or before 90 days was elevated for those with mildly [adjusted hazard ratio (AHR)(1/4)1.7; 95% confidence interval (95% CI)(1/4)1.5-1.9], moderately (AHR(1/4)2.3; 95% CI(1/4)2.0-2.7), and severely (AHR(1/4)4.3; 95% CI(1/4)3.1-5.5) reduced creatinine clearance. Mild (AHR(1/4)1.4; 95% CI(1/4)1.2-1.6), moderate (AHR(1/4)1.9; 95% CI(1/4)1.5-2.3), and severe (AHR(1/4)3.6; 95% CI(1/4) 2.4-5.5) insufficiency were also associated with increased mortality after 90 days, when compared with those with normal renal function. Trends were similar when renal function was estimated with Modification of Diet in Renal Disease or serum creatinine. CONCLUSION: Renal insufficiency at time of ART initiation was prevalent and associated with increased mortality risk among adults in this population. These results have particular relevance for settings like Zambia, where tenofovir--a drug with known nephrotoxicity--has been adopted as part of first-line therapy. This emphasizes the need for resource-appropriate screening algorithms for renal disease, both as part of ART eligibility and pretreatment assessment.
OBJECTIVE: To examine the association between baseline renal insufficiency and mortality among adults initiating antiretroviral therapy (ART) in an urban African setting. DESIGN: Open cohort evaluation. METHODS: We examined mortality according to baseline renal function among adults initiating ART in Lusaka, Zambia. Renal function was assessed by the Cockcroft-Gault method, the Modification of Diet in Renal Disease equation, and serum creatinine. RESULTS: From April 2004 to September 2007, 25 779 individuals started ART with an available creatinine measurement at baseline. When creatinine clearance was calculated by the Cockcroft-Gault method, 8456 (33.5%) had renal insufficiency: 73.5% were mild (60-89 ml/min), 23.4% moderate (30-59 ml/min), and 3.1% severe (<30 ml/min). Risk for mortality at or before 90 days was elevated for those with mildly [adjusted hazard ratio (AHR)(1/4)1.7; 95% confidence interval (95% CI)(1/4)1.5-1.9], moderately (AHR(1/4)2.3; 95% CI(1/4)2.0-2.7), and severely (AHR(1/4)4.3; 95% CI(1/4)3.1-5.5) reduced creatinine clearance. Mild (AHR(1/4)1.4; 95% CI(1/4)1.2-1.6), moderate (AHR(1/4)1.9; 95% CI(1/4)1.5-2.3), and severe (AHR(1/4)3.6; 95% CI(1/4) 2.4-5.5) insufficiency were also associated with increased mortality after 90 days, when compared with those with normal renal function. Trends were similar when renal function was estimated with Modification of Diet in Renal Disease or serum creatinine. CONCLUSION:Renal insufficiency at time of ART initiation was prevalent and associated with increased mortality risk among adults in this population. These results have particular relevance for settings like Zambia, where tenofovir--a drug with known nephrotoxicity--has been adopted as part of first-line therapy. This emphasizes the need for resource-appropriate screening algorithms for renal disease, both as part of ART eligibility and pretreatment assessment.
Authors: Lynda Anne Szczech; Donald R Hoover; Joseph G Feldman; Mardge H Cohen; Stephen J Gange; Lisa Goozé; Nancy R Rubin; Mary A Young; Xiaotao Cai; Qiuhu Shi; Wei Gao; Kathryn Anastos Journal: Clin Infect Dis Date: 2004-09-27 Impact factor: 9.079
Authors: Marianne A B van der Sande; Maarten F Schim van der Loeff; Akum A Aveika; Saihou Sabally; Toyin Togun; Ramu Sarge-Njie; Abraham S Alabi; Assan Jaye; Tumani Corrah; Hilton C Whittle Journal: J Acquir Immune Defic Syndr Date: 2004-10-01 Impact factor: 3.731
Authors: Lynda Anne Szczech; Samir K Gupta; Ramez Habash; Antonio Guasch; Robert Kalayjian; Richard Appel; Timothy A Fields; Laura P Svetkey; Katherine H Flanagan; Paul E Klotman; Jonathan A Winston Journal: Kidney Int Date: 2004-09 Impact factor: 10.612
Authors: Joel E Gallant; Schlomo Staszewski; Anton L Pozniak; Edwin DeJesus; Jamal M A H Suleiman; Michael D Miller; Dion F Coakley; Biao Lu; John J Toole; Andrew K Cheng Journal: JAMA Date: 2004-07-14 Impact factor: 56.272
Authors: Alice Wei; Godfrey C Burns; Brent A Williams; Nazim B Mohammed; Paul Visintainer; Steven L Sivak Journal: Kidney Int Date: 2003-10 Impact factor: 10.612
Authors: Corinne Isnard Bagnis; Gilbert Deray; Alain Baumelou; Moglie Le Quintrec; Jean Louis Vanherweghem Journal: Am J Kidney Dis Date: 2004-07 Impact factor: 8.860
Authors: S Ole-Nguyaine; J A Crump; G S Kibiki; K Kiang; J Taylor; W Schimana; J A Bartlett; J F Shao; J D Hamilton; N M Thielman Journal: Ann Trop Med Parasitol Date: 2004-03
Authors: Lloyd Mulenga; Patrick Musonda; Albert Mwango; Michael J Vinikoor; Mary-Ann Davies; Aggrey Mweemba; Alexandra Calmy; Jeffrey S Stringer; Olivia Keiser; Benjamin H Chi; Gilles Wandeler Journal: Clin Infect Dis Date: 2014-02-27 Impact factor: 9.079
Authors: Benjamin H Chi; Albert Mwango; Mark Giganti; Lloyd B Mulenga; Bushimbwa Tambatamba-Chapula; Stewart E Reid; Carolyn Bolton-Moore; Namwinga Chintu; Priscilla L Mulenga; Elizabeth M Stringer; Robert Sheneberger; Peter Mwaba; Jeffrey S A Stringer Journal: J Acquir Immune Defic Syndr Date: 2010-05-01 Impact factor: 3.731
Authors: Benjamin H Chi; Ronald A Cantrell; Albert Mwango; Andrew O Westfall; Wilbroad Mutale; Mohammed Limbada; Lloyd B Mulenga; Sten H Vermund; Jeffrey S A Stringer Journal: Am J Epidemiol Date: 2010-03-10 Impact factor: 4.897